urea has been researched along with Huntington Disease in 7 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| " ARG2 protein is not reduced in the prodromal stage, though enzyme activity is reduced, indicating that altered Mn bioavailability as a cofactor leads to the deficient enzymatic activity." | 1.46 | Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model. ( Aschner, M; Bichell, TJV; Bowman, AB; Bradley, EM; Bryan, M; Colbran, RJ; Di Pardo, A; Dudek, K; Fisher, N; Halbesma, T; Holt, HK; Horning, K; Kwakye, GF; Maglione, V; Neely, MD; Osmand, A; Stubbs, AD; Tidball, AM; Tipps, KG; Uhouse, MA; Umashanker, P; Wegrzynowicz, M, 2017) |
| "We conclude that Huntington's disease is not associated with a generalised disturbance of quinolinic acid metabolism, however, a local hyperproduction of quinolinic acid cannot be excluded from our results." | 1.27 | Normal excretion of quinolinic acid in Huntington's disease. ( Brown, RR; Garnett, ES; Heyes, MP, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Handley, RR | 1 |
| Reid, SJ | 1 |
| Brauning, R | 1 |
| Maclean, P | 1 |
| Mears, ER | 1 |
| Fourie, I | 1 |
| Patassini, S | 1 |
| Cooper, GJS | 1 |
| Rudiger, SR | 1 |
| McLaughlan, CJ | 1 |
| Verma, PJ | 1 |
| Gusella, JF | 1 |
| MacDonald, ME | 1 |
| Waldvogel, HJ | 1 |
| Bawden, CS | 1 |
| Faull, RLM | 1 |
| Snell, RG | 1 |
| Chen, CM | 3 |
| Lin, YS | 1 |
| Wu, YR | 2 |
| Chen, P | 1 |
| Tsai, FJ | 2 |
| Yang, CL | 1 |
| Tsao, YT | 1 |
| Chang, W | 1 |
| Hsieh, IS | 1 |
| Chern, Y | 3 |
| Soong, BW | 2 |
| Bichell, TJV | 1 |
| Wegrzynowicz, M | 1 |
| Tipps, KG | 1 |
| Bradley, EM | 1 |
| Uhouse, MA | 1 |
| Bryan, M | 1 |
| Horning, K | 1 |
| Fisher, N | 1 |
| Dudek, K | 1 |
| Halbesma, T | 1 |
| Umashanker, P | 1 |
| Stubbs, AD | 1 |
| Holt, HK | 1 |
| Kwakye, GF | 1 |
| Tidball, AM | 1 |
| Colbran, RJ | 1 |
| Aschner, M | 1 |
| Neely, MD | 1 |
| Di Pardo, A | 1 |
| Maglione, V | 1 |
| Osmand, A | 1 |
| Bowman, AB | 1 |
| Chiang, MC | 2 |
| Chen, HM | 2 |
| Lai, HL | 1 |
| Chen, HW | 1 |
| Chou, SY | 1 |
| England, JL | 1 |
| Kaganovich, D | 1 |
| Lee, YH | 1 |
| Chang, HH | 1 |
| Wu, YC | 1 |
| Liu, CS | 1 |
| Niu, DM | 1 |
| Wu, JY | 1 |
| Chen, YT | 1 |
| Heyes, MP | 1 |
| Garnett, ES | 1 |
| Brown, RR | 1 |
7 other studies available for urea and Huntington Disease
| Article | Year |
|---|---|
Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Topics: Adult; Animals; Animals, Genetically Modified; Corpus Striatum; Disease Models, Animal; Female; Huma | 2017 |
High Protein Diet and Huntington's Disease.
Topics: Adult; Citrulline; Dietary Proteins; Disease Progression; Female; Humans; Huntington Disease; Male; | 2015 |
Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.
Topics: Animals; Arginase; Corpus Striatum; Disease Models, Animal; Huntington Disease; Male; Manganese; Mic | 2017 |
The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Disease Models, Animal; Female; Hu | 2009 |
Polyglutamine shows a urea-like affinity for unfolded cytosolic protein.
Topics: Animals; Cell Line; Cytosol; Humans; Huntington Disease; Microscopy, Confocal; Peptides; Protein Den | 2011 |
Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease.
Topics: Animals; Brain-Derived Neurotrophic Factor; CCAAT-Enhancer-Binding Protein-alpha; Citrulline; Diet; | 2007 |
Normal excretion of quinolinic acid in Huntington's disease.
Topics: Adolescent; Adult; Creatinine; Female; Humans; Huntington Disease; Male; Middle Aged; Pyridines; Qui | 1985 |